In recent years, several studies have shown a strong association between chronic inflammation and long-term morbidity and mortality in patients with end-stage renal disease (ESRD) on hemodialysis (HD) [1] . Proinflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-a (TNF-a) are believed to be key orchestrators of this inflammatory response. These cytokines have been implicated as key factors that link malnutrition, accelerated atherogenesis, and excessive morbidity and mortality in ESRD patients on HD [2] . In addition to proinflammatory cytokines, inflammatory stimuli also lead to the expression and release of anti-inflammatory cytokines, particularly interleukin-10 (IL-10). Previous studies have shown that IL-10, released by endotoxinstimulated monocytes, inhibits production of IL-1b, TNF-a, and IL-6 [3] . As its expression is relatively delayed, release of IL-10 provides an efficient autocrine mechanism for regulating proinflammatory cytokine production [4] . However, recent studies have shown that there is considerable interindividual variation in the maximal capacity to produce different cytokines in response to mitogen stimulation in vitro [5] . Furthermore, overall expression and production of cytokines is, in part, genetically determined. Stable allelic variants for several cytokine genes, arising from nucleotide polymorphisms within the regulatory region, have been described in recent years. Polymorphisms involving the 5 -flanking region (promoter) of the TNF-a, IL-6, and IL-10 genes affecting transcriptional activity and, therefore, of functional relevance have been identified [6] .
In this study, we determined the relative frequency of specific alleles/genotypes of IL-6, TNF-a, and IL-10 in a cohort of 183 patients with ESRD on HD, and evaluated the relationship of specific alleles/genotypes and combinations of genotypes to indices of comorbidity and functional status, and biological and nutritional markers.
METHODS

Subjects
The study cohort consisted of 217 patients with ESRD on maintenance HD recruited to the baseline phase of the Hemodialysis (HEMO) Study from two Boston centers. The HEMO Study was sponsored by the United States National Institute of Diabetes, Digestive, and Kidney Diseases, and the full-scale trial began in 1995. Details regarding the design of the HEMO Study have been published elsewhere [7] . In brief, this was a multicenter, prospective, randomized clinical trial designed to evaluate the effect of dialyzer urea and b 2 -microglobulin clearances on the morbidity and mortality of patients. Patients were eligible for inclusion into the HEMO Study if they were between the ages of 18 and 80 years, had been receiving chronic HD three times per week, and had residual renal clearance of urea of less than 1.5 mL/min/35 L of urea distribution volume. Those patients in acute or chronic care hospitals, with active malignancy, decompensated cardiac, hepatic, or pulmonary disease, serum albumin <2.6 g/dL, interdialytic urea clearance >1.5 mL/min, pregnancy, or a scheduled or recently (<6 months) failed transplant were excluded.
Blood samples for genotyping were available for 187 patients. Of these, 102 patients were Caucasian and 81 were African American. As there were only four patients representing other races, analysis was confined to these 183 patients. Randomization to either a standard or high dose of dialysis, and to either a low-or high-flux dialyzer was carried out in 175 patients in whom outcomes on follow-up were studied.
This ancillary study was approved by the Human Investigation Review Committee (HIRC), and all participants provided written, informed consent. Cares for self 20 (9) 60
Self-care with minimal help 18 (8) 50
Self-care with considerable help 15 (7) 40 Disabled; needs special care 13 (6)  30 Severely disabled -20
Very sick; hospitalization needed -10
Moribund -
Data procurement
Demographic, medical, and socioeconomic information was obtained once patients were enrolled into the baseline phase of the study. During the fifth week of the study, while the patients were still in the baseline phase, their comorbid medical conditions were assessed and recorded on a standardized form. The form was completed at each clinical center by specially trained study coordinators. The information available for completion of the form included chart progress notes, list of current medications, and the most recent laboratory data, chest x-ray report, electrocardiogram, and hospital discharge summary, and was supplemented by interviews of the patients, family members, primary nephrologists, and dialysis staff as necessary.
The comorbidities were cataloged using the Index of CoExisting Diseases (ICED), a coding system that classifies the presence and severity of 19 different diseases and 11 physical impairments [8] . Disease severity was scored on a scale from 0 to 3, with 0 indicating the absence of disease, and increasing values indicating increasing severity of the disease. The highest scores of Index of Disease Severity (IDS) and Index of Physical Impairment (IPI) were combined to create the ICED score, from 0 to 3 (Table 1) . Functional status was assessed by means of the Karnofsky Index (KI) [9] . The KI is an overall indicator of the patient's level of physical functioning and is used frequently in clinical research. KI scores range from 10 (lowest level) to 100 (highest level) ( Table 1) . Clinical assessment of nutritional status included anthropometric measurements and body mass index.
The primary outcome defined in the HEMO Study was death from any cause. Three secondary outcomes were included: one a composite of death from any cause and the first decline of >15% from baseline in serum albumin, and the second, a composite of first cardiac hospitalization and cardiac death. The third, cardiovascular death, referred to deaths caused by ischemic heart disease (IHD), congestive heart failure (CHF), arrhythmias, or other heart disease, or cerebrovascular disease.
Blood samples were obtained predialysis, as part of the routine clinical protocol, within one month of enrollment for measurement of routine laboratory parameters [including predialysis and postdialysis urea for calculation of dialysis dose (Kt/V) and normalized protein catabolic rate (nPCR)]. Equilibrated postdialysis urea from the rate equation of Daugirdas and Schneditz was used for calculation of Kt/V and nPCR [10] . A 30-mL heparinized blood sample was also collected as part of an ancillary study investigating the role of dialyzer flux and dialysis dose on cytokine production by peripheral blood mononuclear cells (PBMC). Plasma samples were stored at -80 • C until IL-6 measurements and isolated PBMC aliquots were utilized for DNA extraction and genotyping, as well as endotoxin-stimulated cytokine production.
PBMC isolation and DNA extraction
PBMC were harvested as previously described from whole blood, using Ficoll-Hypaque density gradient separation technique [11] . Cell aliquots (2.5 × 10 6 PBMC/mL) were resuspended in RPMI 1640 cell culture medium supplemented with L-glutamine, NaHCO 3 , HEPES, penicillin, and streptomycin, and stored at -80 • C until DNA extraction.
Genomic DNA was extracted using a spin column method (QIAamp DNA Mini Kit; Qiagen, Valencia, CA, USA). In brief, 2.5 × 10 6 PBMC were treated with 20 lL of proteinase K (Qiagen), followed by the addition of 200 lL of sodium dodecyl sulfate (SDS) to lyse the cells. The homogeneous solution was incubated at 56 • C for 10 minutes, and 200 lL of 100% ethanol was added to precipitate DNA. The mixture was then applied to the QI-Aamp spin column, and after two washes with 500 lL of wash buffer, genomic DNA was eluted by the addition of 200 lL of elution buffer. Final DNA concentrations were 50 to 200 ng/mL determined by minigel electrophoresis.
Cytokine promoter genotyping
Polymerase chain reaction (PCR)-sequence-specific primer (SSP) approach was used to analyze one to three single nucleotide allelic variations in the promoter regions of IL-6, TNF-a, and IL-10. Polymorphic alleles at -174 (G→C), -308 (G→A), and -1082 (G→A) of the IL-6, TNF-a, and IL-10 promoter regions, respectively, were studied. PCR was performed on the purified DNA using a Cytokine Genotyping Tray (One Lambda, Inc., Canoga Park, CA, USA), which provided sequencespecific oligonucleotide primers for the three cytokines.
It is based on the principle that completely matched oligonucleotide primers are more efficiently used in amplifying a target sequence than a mismatched oligonucleotide primer by recombinant Taq polymerase. Primer pairs are designed to have perfect matches only with a single allele or group of alleles. Under strictly controlled PCR conditions, perfectly matched primer pairs result in amplification of target sequences (i.e., a positive result), while mismatched primer pairs do not result in amplification (i.e., a negative result). In brief, 20 lL of genomic DNA solution was added to the D-mix, which contains the desoxynucleoside triphosphate (dNTPs) and reaction buffer, for the cytokine genotyping. Taq polymerase (1.1 lL; Gibco BRL, Grandland, NY, USA) was then added to the D-mix, vortexed for 15 seconds, and 10 lL of the D-mix mixture was transferred to a 96-well microtiter genotyping tray with dried primers in each reaction well. A Perkin-Elmer 9600 thermocycler (Perkin-Elmer-Cetus, Norwalk, CT, USA) was used to amplify the promoter regions by PCR. Samples were subjected to 10 cycles at 96 • C for 10 seconds, and 63 • C for 60 seconds, followed by 20 cycles at 96 • C for 10 seconds, annealing at a temperature of 59 • C for 50 seconds and 72 • C for 30 seconds. After the PCR process, the amplified DNA fragments were separated by agarose gel electrophoresis and visualized by staining with ethidium bromide and exposure to ultraviolet light in a UV transilluminator. Interpretation of PCR-SSP results is based on the presence or absence of a specific amplified DNA fragment. An internal control primer pair was included in every PCR reaction to exclude nonspecific amplification affected by several factors, such as pipetting errors, poor DNA quality, presence of inhibitors, and others. A positive reaction for a specific cytokine allele or allele group is visualized on the gel as an amplified DNA fragment between the internal control product band and the unincorporated primer band.
Phenotype assignments
Cytokine production phenotype was assigned based on the genetic information. These production phenotypes for IL-6, TNF-a, and IL-10 were based on previously published in vitro transfection studies using constructs of the relevant alleles, studies on whole blood, and PBMC cultures stimulated with endotoxin, and in vivo studies measuring plasma levels of the relevant cytokines [12] . Specifically, high-, intermediate-, or low-producer phenotypes were assigned to IL-6, TNF-a, and IL-10 as follows: IL-6, position -174: high-producer genotype (G/G and G/C) or low-producer genotype (C/C); TNF-a, position -308: high-producer genotype (A/A and G/A) and lowproducer genotype (G/G); and IL-10, position −1082: high-producer genotype (G/G), intermediate-producer genotype (G/A), and low-producer genotype (A/A). 
Plasma IL-6 and PBMC cytokine production
Plasma IL-6 was measured by commercial, highsensitivity sandwich enzyme-linked immunosorbent assay (ELISA) kits (Quantikine TM Human IL-6 HS ELISA; R&D Systems, Minneapolis, MN, USA). The minimum detection limit for this assay was 0.039 pg/mL. To measure stimulated TNF-a and IL-10 production, 0.5 mL suspensions of PBMC (2.5 × 10 6 cells) were incubated with 0.5 mL of RPMI containing 20 ng/mL endotoxin (ET) (Escherichia coli, serotype 055:B5; Sigma, St. Louis, MO, USA) (final ET concentration 10 ng/mL) at 37 • C with 5% CO 2 . At the end of 24 hours, the cell suspensions were subjected to three freeze-thaw (−70 • C) cycles for measurement of total TNF-a and IL-10 production (cell-associated and secreted). TNF-a and IL-10 were measured using commercial quantitative sandwich enzyme immunoassays (R&D Systems). The detection limits for IL-10 and TNF-a were 4.4 pg/mL and 1.5 pg/mL, respectively. All samples were tested in duplicate and in appropriate dilutions, and all samples for a given assay were tested simultaneously.
Statistical analysis
Analysis was performed using the Statistical Analysis Software (SAS), version 8.2 (Cary, NC). The independent sample t test and one-way analysis of variance (ANOVA) with the Bonferroni correction for multiple comparisons were used to compare differences between groups, and the chi-square test was used for differences in proportions and linear trends. Univariate and multivariate analyses were performed to test the effect of different cytokine genotypes, genotype combinations, and other relevant variables on comorbidity (ICED score), functional status (Karnofsky Index), serum albumin, and nutritional markers (body mass index, anthropometric measurements, and nPCR). IDS scores for diabetes were expressed independently, and the ICED scores used in analysis did not include the IDS scores for diabetes. All multivariate models were adjusted for age, gender, race, dialysis vintage, and diabetes. We tested for interactions between the different cytokine genotypes and other variables in the model.
Ordinary least squares (OLS) regression model was fitted to albumin and body mass index (BMI). The distribution of serum albumin was fairly normal. The distribution of BMI was skewed to the right; hence, it was log-transformed for purposes of analyses.
Proportional odds (PO) models were used to analyze ordinal response data with more than two levels, namely the ICED score and the KI (PO models fit the cumulative logits by performing ordered logistic regression). The outcomes were higher or less favorable ICED score, and lower or less favorable Karnofsky score. We checked for the ordinality assumption for each covariate by plots of means for each level of ICED score and KI and found that this assumption was met for all variables that were significant in the univariate analysis. The proportionality assumption was checked using a graphical approach developed by Petterson and Harrell [13] using residuals for each covariate. Univariate, as well as age, race, gender, dialysis vintage, and diabetes adjusted multivariate PO models were performed for all genotypes and genotype combinations, with ICED and Karnofsky scores as the outcome variables, as outlined above.
The effect of individual cytokine genotypes and genotype combinations on the selected secondary outcomes of the HEMO Study were explored using Cox proportional hazards regression. Models were adjusted for the dialysis dose and flux grouping assignment from the randomization of the parent study, in addition to baseline covariates.
P values < 0.05 were considered significant.
RESULTS
Demographic characteristics and genotype frequencies in the cohort
Demographic characteristics and baseline laboratory data are provided in Table 2 . Gel interpretation, and therefore, allele identification for IL-6 and IL-10 could not be reliably performed for five and three patients, respectively. Figure 1 presents the frequencies of the different cytokine genotypes in the cohort, and Table 3 shows the frequency distribution of individual genotypes and alleles by race.
Relationship between individual cytokine genotypes and ICED score
A higher proportion of patients with the IL-6 highproducer genotype had ICED scores of 2 and 3 (higher comorbidity) compared with those with the IL-6 lowproducer genotype (P = 0.03). Similarly, a higher proportion of patients with the TNF-a high-producer genotypes had scores of 2 and 3 as compared with the TNF-a lowproducer genotype, although this did not reach statistical significance (P = 0.06). There was no significant difference in ICED score distribution between the different IL-10 genotypes (P = 0.35) ( Table 5 ).
On both univariate and multivariate analysis (Table 6) , the presence of the IL-6 high-producer genotype was associated with increased odds (over four-fold) of higher ICED scores compared to the IL-6 low-producer genotype. The multivariate model was adjusted for age, gender, race, diabetes, and duration on HD; of these covariates, only diabetes (OR = 3.2, 95%CI, 1.7 to 5.9, P = <0.001) was significant in the model. Because the distribution of individual IL-6 genotypes and alleles appeared to differ by race, a stratified analysis was undertaken. The presence of the IL-6 high-producer genotype in Caucasians was still associated with a four-fold higher risk of higher ICED scores (P = 0.05), but this did not reach statistical significance after adjustment for covariates (P = 0.06). The analysis in African Americans was limited by the extremely small number of patients with the IL-6 low-producer genotype (C/C) (N = 3).
The presence of the TNF-a high-producer genotype was associated with a two-fold increased odds of higher ICED scores compared with the TNF-a low-producer genotype (95% CI, 1.03 to 3.88, P = 0.04), after adjustment for the above covariates. Here again, diabetes was the only covariate with a significant association with higher ICED scores. The association of IL-10 genotypes with ICED scores did not reach statistical significance.
Relationship between individual cytokine genotypes and Karnofsky Index
Patients with the IL-6 high-producer genotype or the TNF-a high-producer genotype had a lower KI (more functional impairment) compared with those with the respective low-producer genotypes. In contrast, patients with the IL-10 high-and intermediate-producer genotypes had higher KI compared with those with the IL-10 low-producer genotype ( Table 5 ). The univariate analysis revealed significant relationships between KI and IL-6, TNF-a, and IL-10 genotypes. On multivariate analysis, after adjustment for age, gender, race, duration on dialysis, and diabetes, the odds of having a lower KI (more functional impairment) were higher in patients with the IL-6 and TNF-a high-producer genotypes compared with their respective low-producer genotypes (OR = 4.9, P = 0.04, and OR = 2.2, P = 0.02, respectively) ( Table 6 ). The relationship between IL-10 genotype and KI did not reach significance after adjustment for covariates. Of the covariates, older age and diabetes were significantly associated with a lower KI; univariate relationships showed that each increasing year of age was associated with a 2% higher likelihood of a lower KI (OR = 1.02, 95% CI, 1.0 to 1.05, P = 0.05), and the presence of diabetes was associated with a 2.6-fold higher likelihood (OR = 2.55, 95% CI, 1.45 to 4.47, P = 0.001). These relationships were similar in the multivariate analysis.
As with ICED, a race-stratified analysis was carried out to evaluate the relationship between IL-6 genotypes and KI. The analysis had to be limited to Caucasians, however, because there were very few African Americans with the IL-6 low-producer genotype (N = 3). Caucasian patients with the IL-6 high-producer genotype had lower KI, but the association did not reach statistical significance (OR = 8.14, 95% CI, 0.89 to 74.3, P = 0.06).
Relationship between individual cytokine genotypes and serum albumin
Patients with the TNF-a high-producer genotype had lower serum albumin compared with those with the lowproducer genotype. There were no significant differences in serum albumin among the various IL-6 and IL-10 genotypes.
On univariate analysis, patients with the TNF-a highproducer genotype were estimated to have mean serum albumin levels 0.13 g/dL lower than patients with the TNF-a low-producer genotype ( Table 5 ). This relationship was seen even after adjustment for covariates in the multivariate model. Males had adjusted serum albumin levels 0.23 g/dL higher than females; there was no association between serum albumin and the other covariates.
Relationship between individual cytokine genotypes and other nutritional indices
There were no significant associations between individual TNF-a, IL-6, and IL-10 genotypes and BMI, anthropometric measurements, or nPCR. Serum albumin showed a poor but significant correlation with nPCR (r = 0.17, P = 0.01), but not with BMI or other anthropometric measurements.
Association between cytokine genotype combinations and comorbidity, functional, and nutritional indices
Stratification by cytokine genotype combinations yielded three categories for the IL-6/TNF-a and IL-6/IL-10 combinations, and four categories for the TNF-a/IL-10 combination (Table 6 ). There were no patients with the low-IL-6/high-TNF-a producer genotype combination, and only two patients with the low-IL-6/low-IL-10 producer genotype combination who were not included in the analysis. This stratified analysis therefore allowed comparisons of the effect of genotype combinations, as well as the effect of each cytokine independent of the other.
Cytokine genotype combinations and ICED score
IL-6/TNF-a genotype combinations. Figure 2A shows that a higher proportion of patients with the high-IL-6/high-TNF-a producer genotype combination had ICED scores of 2 and 3 (higher comorbidity) compared with patients with the high-IL-6/low-TNF-a and low-IL-6/low-TNF-a producer genotype combination. (P = 0.01, Mantel-Hansel v 2 for linear trend). On multivariate analysis, after adjustment for age, gender, race, and dialysis vintage, the odds of a higher ICED score was greater with the high-IL-6/high-TNF-a and the high-IL-6/low-TNF-a genotype combination relative to patients with the low-IL-6/low-TNF-a genotype combination (OR of 8.3 and 4.2, respectively) ( Table 7) . The difference in OR between the high-IL-6/high-TNF-a and high-IL-6/low-TNF-a producer genotype combination was also significant (P = 0.05, Wald v 2 test), suggesting that the risk conferred by one cytokine genotype was influenced by the other.
IL-6/IL-10 genotype combination. A lower proportion of patients with the low-IL-6/high-IL-10 producer genotype combination had ICED scores of 2 and 3 compared with those with the high-IL-6/high-IL-10 producer genotype combination, which was, in turn, lower than among patients with the high-IL-6/low-IL-10 genotype combinations (P = 0.03, Mantel-Hansel v 2 test for linear trend) ( Fig. 2B) . In the multivariate model, the odds of a higher ICED score was greater among patients with the high-IL-6/high-IL-10 and high-IL-6/low-IL-10 producer genotype combinations relative to those with the low-IL-6/high-IL-10 producer genotype combination (OR of 3.68 and 4.80, respectively), but only the comparison between the two polar combinations, the high-IL-6/high-IL-10 and low-IL-6/high-IL-10 producer genotype combinations, reached significance (Table 7) .
TNF-a/IL-10 genotype combinations. The TNF-a/IL-10 genotype combinations showed a similar linear trend in the proportion of patients with higher ICED scores ranging from the lowest in those with the low-TNFa/high-IL-10 to the highest in those with the high-TNF-a/low-IL-10 producer genotype combination, on univariate analysis (Fig. 2C) . On multivariate analysis, only the comparison between the two polar combinations, the low-TNF-a/high-IL-10 and the high-TNF-a/low-IL-10 producer genotypes, reached statistical significance after adjustment for other covariates.
Cytokine genotype combinations and the Karnofsky Index
IL-6/TNF-a genotype combinations. The mean KI was significantly different among the three IL-6/TNF-a genotype combinations, as seen in Figure 3A (P = 0.02). Patients with the high-IL-6/high-TNF-a producer genotype combination had the lowest, and those with the low-IL-6/low-TNF-a genotype combination the highest KI (significant by Bonferroni correction, P = 0.02; other pairwise comparisons not significant). After adjustment for age, gender, race, and diabetes, patients with the high-IL-6/high-TNF-a producer genotype combination had significantly higher odds of having a low KI, relative to those who carried the low-IL-6/low-TNF-a producer genotype combination (Table 7 ). Although the difference in OR between the high-IL-6/low-TNF-a genotype combination and the low-IL-6/low-TNF-a producer genotype combination did not reach significance (P = 0.07), the comparison between the high-IL-6/high-TNF-a genotype combination and the high-IL-6/low-TNF-a genotype combination did (P = 0.05, Wald v 2 test), suggesting that the risk conferred by one cytokine genotype was influenced by the other (Table 7) .
IL-6/IL-10 genotype combination. The mean KI was significantly different among the three IL-6/IL-10 genotype combinations, as seen in Figure 3B (P = 0.008). Patients with the high-IL-6/low-IL-10 producer genotype combination had the lowest KI, and those with the low-IL-6/high-IL-10 genotype combination the highest KI. Pairwise comparisons (with the Bonferroni correction) showed that patients with the high-IL-6/low-IL-10 producer genotype combination had a KI that was significantly lower than patients with either the high-IL-6/high-IL-10 producer genotype combination (P = 0.05) or the low-IL-6/high-IL-10 producer genotype combination (P = 0.03), but the difference between the high-IL-6/high-IL-10 and low-IL-6/high-IL-10 producer genotype combinations was not significant (P = 0.41). Multivariate analysis demonstrated a difference between the polar combinations, the high-IL-6/low-IL-10 producer genotype combinations being associated with higher odds of a low KI compared with the low-IL-6/high-IL-10 producer genotype combination (OR of 5.99, Table 7 ). The difference in odds for a lower KI between the high-IL-6/low-IL-10 compared with the high-IL-6/high-IL-10 producer genotype combinations did not reach statistical significance (P = 0.08).
TNF-a/IL-10 genotype combinations. TNF-a/IL-10 genotype combinations again indicated that patients with the low-TNF-a/high-IL-10 genotype combination had the highest KI, with a progressive decrease in KI across the low-TNF-a/low-IL-10, and high-TNF-a/high-IL-10 producer genotype combination, to the lowest score in patients with high-TNF-a/low-IL-10 producer genotype combination (P = 0.01) (Fig. 3C ). Pairwise comparisons (applying the Bonferroni correction) showed a significant difference between the two polar combinations (P = 0.05); other pairwise comparisons did not reach significance. On multivariate analysis, compared with patients with the low-TNF-a/high-IL-10 producer genotype combination, patients with the high-TNF-a/high-IL-10 genotype combination or the high-TNF-a/low-IL-10 producer genotype combination, showed significantly higher odds of having a lower KI (P = 0.03 and 0.01, respectively) ( Table 7 ). The differences in odds between the low-TNF-a/low-IL-10, high-TNF-a/high-IL-10 and high-TNF-a/low-IL-10 producer genotype combinations was not significant. 
Cytokine genotype combinations and nutritional indices
TNF-a/IL-10 genotype combinations. Patients with the high-TNF-a/low-IL-10 producer genotype combination had a significantly lower BMI compared with those with the lowTNF-a/high-IL-10 producer genotype combination (22.4 ± 4.4 kg/m 2 vs. 25.3 ± 5.0 kg/m 2 , P = 0.05). Multivariate analysis for BMI (log-transformed to normalize its distribution), adjusted for age, gender, race, dialysis vintage, and diabetes showed a 12% lower BMI (95% CI, 2 to 22, P = 0.02) in patients with the high-TNF-a/low-IL-10 producer genotype combination compared with patients with the low-TNF-a/high-IL-10 combination. There was no significant association between cytokine genotype combinations and other nutritional indices, including anthropometric measurements, nPCR, or serum albumin levels.
Relationship between cytokine levels and genotypes
Plasma IL-6 levels and results of ex vivo endotoxinstimulated TNF-a and IL-10 production by PBMC are shown in Table 4 . Plasma IL-6 levels were significantly higher in patients with the high-IL-6 producer genotypes (G/G and G/C) compared with those with the low-producer genotype (C/C) (15.01 ± 17.4 vs. 12.2 ± 5.1, P = 0.05). Similarly, there was a significant difference in endotoxin-stimulated IL-10 production by PBMC between patients with the high-(G/G), intermediate-(G/A), and low-(A/A) IL-10 producer genotypes (P = 0.01, Kruskal-Wallis test). Mean PBMC IL-10 production was highest among patients with the high-producer G/G genotype. Pair-wise comparisons showed that the differences between -1082 G/G and A/A, and -1082 G/G and -1082 G/A were significant (P = 0.01 and P = 0.03, respectively, with Bonferroni correction), although the difference between -1082 G/A and A/A did not reach significance. Although endotoxin-stimulated TNF-a production was higher among patients with the highcompared with the low-TNF-a producer genotype, this difference did not reach statistical significance.
Association with clinical outcomes
Follow-up information on outcomes was available in 175 patients who were randomized to high or standard dialysis dose, and to high-or low-flux dialyzer limbs of the HEMO Study. The median duration of follow-up was 824 days (1 to 2376 days). A total of 101 patients (58%) died during follow-up, 102 (58%) had a composite event of albumin decline or death from any cause, 101 (50%) had a composite event of first cardiac hospitalization or cardiac death, and 44 (25%) had a cardiovascular cause for death. Overall actuarial survival in the cohort was 89% at one year, 67% at two years, and 51% at three years. There were no demonstrable associations between individual genotypes or genotype combinations and the above primary and secondary outcomes defined in the HEMO Study.
DISCUSSION
There is considerable evidence for a cytokineorchestrated chronic inflammatory response in patients on long-term HD. Indeed, several studies have shown that plasma levels of proinflammatory cytokines such as IL-1 and TNF-a are elevated among patients on HD [14] . In addition, some, but not all studies have reported a further increase in circulating levels of cytokines during the course of an HD treatment [15, 16] . These cytokines have been incriminated in the short-and long-term morbidity experienced by HD patients. Proinflammatory cytokines such as TNF-a and IL-6 may suppress appetite [17] and induce catabolism [18] , leading to a wasting illness that may be indistinguishable from malnutrition. Bologa et al found a significant correlation between plasma TNFa and IL-6, and the degree of hypoalbuminemia and dyslipoproteinemia among HD patients. This study also found that plasma IL-6 level was a predictor of mortality among these patients [2] . Likewise, Kimmel et al [19] found that elevated plasma levels of TNF-a and IL-6 among HD patients were significantly associated with an increased relative risk of death. We have observed that higher endotoxin-stimulated cytokine synthesis by PBMC predicted morbidity from cardiovascular events [20] . There is, however, considerable interindividual variability in cytokine secretion patterns in response to stimuli. This is determined, at least in part, by polymorphisms within the promoter region of these cytokines, and may have a significant influence on individual susceptibility to cytokine-induced chronic inflammation and its attendant morbidity.
The results of this study demonstrate an important association between single nucleotide polymorphisms within the promoter region of cytokine genes, and indices of comorbidity and function and serum albumin in a cohort of ESRD patients on long-term HD. These associations remained significant despite adjustment for age and diabetes, both of which are established risk factors for poor outcomes. In the present study, a higher proportion of patients with the IL-6 high-producer genotypes had ICED scores of 2 or 3 (moderate to severe comorbidity) and lower Karnofsky scores than patients with the IL-6 low-producer genotype. After adjustment for other covariates, IL-6 genotypes retained a strong association with comorbidity and functionality. The multivariate model indicated that the odds of a higher ICED score was nearly five-fold higher in patients with the IL-6 high-producer genotype compared with patients with the IL-6 low-producer genotype. Despite the low prevalence of the IL-6 low-producer genotype in the cohort, we believe these results are sufficiently robust to indicate a significant association between IL-6 genotypes and comorbidity and functional status in HD patients.
The -174 G→C promoter region polymorphism of the IL-6 gene has been shown to be functionally relevant. Transient transfection experiments using reporter gene constructs containing either allele indicate that the C allele results in suppression of IL-6 transcription in response to endotoxin or IL-1 in HeLa cells [21] . The presence of the C allele has also been associated with lower serum levels of IL-6 in healthy subjects, supporting the in vitro observation of reduced promoter strength [21] . In contrast, Fernandez-Real et al [22] have recently shown that carriers of the G allele at position -174 demonstrated higher plasma IL-6 levels and were more prone to lipid abnormalities. Other investigators have also shown that among patients with coronary artery disease, the G/G genotype is associated with higher plasma IL-6 levels and with longer hospitalization than the presence of the C allele [23] . In the present study, we were able to confirm the association of the G/G and G/C genotypes with higher plasma IL-6 levels relative to patients with the C/C genotype.
The -308 G→A TNF-a polymorphism also showed a significant association with comorbidity, functionality, and serum albumin level. The presence of the -308A allele (also referred to as the TNF2 allele), or the TNF-a high-producer genotype (G/A or A/A) was associated with higher comorbidity, lower Karnofsky scores, and lower serum albumin concentrations than patients with the wild-type TNF-a low-producer genotype (G/G). On multivariate analysis, TNF-a genotypes retained a strong association with ICED scores, Karnofsky Index, and serum albumin levels after adjustment for other covari-ates. As patients with a low serum albumin were excluded from enrollment into the HEMO Study, the effect noted in this study on serum albumin was particularly significant.
The -308A allele has been associated with high promoter activity [6] and has been found to correlate with enhanced spontaneous and stimulated TNF-a production both in vitro and in vivo [12] . Furthermore, the TNF2 polymorphism has been associated with increased morbidity and mortality of severe forms of cerebral malaria [24] , fulminans purpura [25] , and mucocutaneous leishmaniasis [26] . Other investigators have shown that the TNF2 allele is strongly associated with susceptibility to, and mortality from, septic shock [27] , and may also be a susceptibility factor for systemic lupus erythematosus (SLE) [28] . Although in the present study endotoxinstimulated TNF-a response of PBMC was higher among patients with the high-producer G/A and A/A genotypes compared with the G/G genotype, this difference did not reach statistical significance.
Although IL-10 genotypes did not show an independent association with comorbidity or serum albumin concentrations, patients with the IL-10 high-or intermediate-producer genotypes were more likely to have higher Karnofsky scores than patients with the IL-10 lowproducer genotype. Twin studies and family studies have suggested that ∼75% of the variation in IL-10 production is genetically determined and appears to be controlled at the transcriptional level [29] . In vitro studies indicate that the -1082 G allele is associated with higher IL-10 production and the A allele with lower IL-10 production [30] . These observations have been confirmed by transfection studies in U937 monocytic cell lines using appropriate constructs [30] . Indeed, in the present study, we observed higher endotoxin-stimulated IL-10 production by PBMC among patients with the high-producer G/G genotype compared with the other genotypes, confirming earlier observations. Autoimmune inflammatory disorders such as SLE and rheumatoid arthritis, characterized by high proinflammatory cytokine activity, appear to be associated with an increased frequency of the lowproducer A allele [31] . It is therefore possible that genetically determined lower production of IL-10 might influence disease susceptibility and/or severity caused by altered proinflammatory/anti-inflammatory cytokine balance.
Patients with the combination of IL-10 high-or intermediate-producer genotypes with the IL-6 low-producer genotype, or the combination of IL-10 high-or intermediate-producer genotypes with the TNF-a low-producer genotype had less comorbidity and higher Karnofsky scores than patients with the opposite polar genotype combinations. The combination of IL-10 high-or intermediate-producer genotypes with the TNF-a low-producer genotype was also associated with significantly lower BMI. Given the strong regulatory influence of IL-10 on proinflammatory cytokine production, these observations indicate that synergistic or antagonistic effects may come into play with genotype combinations, and these may have a critical role in susceptibility to chronic inflammation and its sequelae in these patients. Indeed, our results demonstrated a gradation of risk in the relationship between outcomes and genotype combinations that would be expected to predispose to a proinflammatory state, with a consistent linear trend demonstrable on univariate analysis. Whereas on multivariate analysis, the change in odds ratio attributable to each cytokine did not consistently reach significance, this could be explained by sample size, as well as a relatively lower prevalence of certain genotypes in this cohort.
The HEMO Study population was a selected dialysis population, weighted toward a relatively healthy prevalent cohort of HD patients, who could be considered long-term survivors on dialysis. Although the restrictions imposed by these selection criteria limit the generalizability of our results, demonstration of an association between cytokine genotypes and clinical indices lends added significance to our observations. Comorbidity and functional status were used as clinical end points, as they are global indices of clinical status, and strong predictors of survival, and therefore, may be more sensitive phenotypes for the consequences of inflammatory processes. This may also explain the lack of a detectable effect of cytokine promoter polymorphisms on the HEMO Study primary and secondary end points. Inflammatory processes may be contributory in only a proportion of these events, and this study probably had inadequate power to detect this aspect of the relationship.
CONCLUSION
Results from this study indicate that single nucleotide polymorphisms in the promoter region of the proinflammatory cytokines IL-6 and TNF-a, and the regulatory monokine IL-10, are strongly associated with indices of comorbidity and function, as well as serum albumin in ESRD patients on long-term HD. Their influence on clinical outcomes in patients with earlier stages of chronic kidney disease will be the focus of further studies.
